Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

JDQ443

Drug and asset intelligence for JDQ443 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

ClinicalJuly 3, 2026

Novartis is evaluating JDQ443 as a first-line treatment for KRAS G12C-mutated NSCLC with low PD-L1 expression.

No catalysts indexed for this entity yet.

Topline Data

Monitor trial results and potential regulatory submissions based on efficacy and safety outcomes.

July 3, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.